Boston,
MA. April 19 — Bioxytran, Inc. (BIXT) announced that it has filed a
registration statement on Form S-1 with the U.S. Securities and Exchange
Commission relating to a proposed offering of shares of its common
stock. The number of shares to be offered and the price range for the
proposed offering have not yet been determined. Bioxytran, Inc. has
currently traded under the ticker symbol “BIXT.”
Bioxytran will manage the offering, however, reserves
the right to utilize a placement agent or underwriter once the SEC has
approved the registration statement.
The offering will be made only by means of a
prospectus. Copies of the preliminary prospectus relating to this
offering, when available, may be obtained directly from the company by
telephone or by email to Bioxytran at info@bioxytraninc.com.
A registration statement relating to these securities
has been filed with the Securities and Exchange Commission but has not
yet become effective. These securities may not be sold nor be offered to
buy or be accepted prior to the time the registration statement becomes
effective.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Bioxytran, Inc.
Based in Newton, MA, Bioxytran Inc. is a
developmental stage biopharmaceutical company developing anti-necrosis
drugs that treat hypoxia. Hypoxia is a condition resulting in an
insufficient supply of oxygen to bodily tissues, can cause a variety of
severe, harmful medical conditions including cancer growth and cell
death.
The company is focusing on the development and
commercialization of first-in-class treatments to prevent brain damage
resulting from hypoxic conditions following brain stroke and trauma. The
Company’s lead product candidate, BXT-25, is an anti-necrosis drug that
carries oxygen to tissues when the flow of blood is blocked. It will be
tested as a potent resuscitative agent to treat ischemic brain strokes,
caused by severely reduced blood flow to the brain. In addition, the
company plan to test another drug candidate, BXT-252, as a resuscitative
agent in a variety of wound-healing applications, as well as in organ
transplantation and cancer contexts.
Contact: David Platt, CEO of Bioxytran, Inc.
Phone: (617) 494-1199
Email: info@bioxytraninc.com
